Nanoviricides (NNVC) Interest Coverage Ratio (2013 - 2025)
Nanoviricides (NNVC) posted Interest Coverage Ratio of 449171.25 for Q3 2025, down 1138.18% sequentially from 36276.71 in Q1 2025, and down 935.08% YoY from 53788.04 in Q3 2024.
Nanoviricides (NNVC) Interest Coverage Ratio (2013 - 2025) Analysis & Trends
Nanoviricides has reported Interest Coverage Ratio for 13 years, with the latest figure at 449171.25 in Q3 2025.
- Quarterly Interest Coverage Ratio fell 935.08% year-over-year to 449171.25 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 2055123.75 (down 1454.27% YoY) and the FY2025 annual result came in at 351.72, down 105.71% from the prior year.
- Interest Coverage Ratio fell to 449171.25 in Q3 2025 per NNVC's latest filing, from 36276.71 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 55.67 in Q3 2023 and troughed at 449171.25 in Q3 2025.
- A 5-year average of 42242.62 and a median of 2425.44 in 2021 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio jumped 99.16% in 2023, then slumped 77849.41% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 20216.59 in 2021, then gained by 3.49% to 19510.57 in 2022, then surged by 99.16% to 164.08 in 2023, then slumped by 8322.07% to 13819.13 in 2024, then tumbled by 3150.36% to 449171.25 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 449171.25, 36276.71, and 13819.13 for Q3 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -449,171.25 |
| Mar 31, 2025 | -36,276.71 |
| Dec 31, 2024 | -13,819.13 |
| Sep 30, 2024 | -43,394.99 |
| Dec 31, 2023 | -164.08 |
| Sep 30, 2023 | -55.67 |
| Dec 31, 2022 | -19,510.57 |
| Sep 30, 2022 | -1,922.23 |
| Jun 30, 2022 | -1,068.40 |
| Mar 31, 2022 | -714.58 |
| Dec 31, 2021 | -20,216.59 |
| Sep 30, 2021 | -2,928.66 |
| Jun 30, 2021 | -1,316.16 |
| Mar 31, 2021 | -837.65 |
| Dec 31, 2020 | -61.46 |
| Sep 30, 2020 | -51.71 |
| Jun 30, 2020 | 1,049.73 |
| Mar 31, 2020 | 1,065.53 |
| Dec 31, 2019 | -395.65 |
| Jun 30, 2018 | -7.25 |